Reducing diabetes distress in teenagers
Official title: A Hybrid Effectiveness-implementation Trial of an Intervention to Reduce Diabetes-specific Emotional Distress in Teenagers
Run by Ann & Robert H Lurie Children's Hospital of Chicago · NCT06709755 · Data updated 2026-11-12
This study is testing a new program to help teenagers with Type 1 Diabetes feel less stressed about their condition by comparing in-person and online support sessions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years to 18 Years |
| Sex | All |
| Enrollment | 360 (estimated) |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | July 10, 2024 |
| Main results expected | March 15, 2029 |
| Study ends | March 15, 2029 |
| Registry record updated | May 29, 2026 |
| Trial ID | NCT06709755 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are teenagers diagnosed with Type 1 Diabetes for at least one year, who are fluent in English and can provide consent.
✕Probably not a fit
Patients with cognitive or developmental disorders or those who are wards of the state may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness and implementation of the Supporting Teen Problem Solving (STePS) intervention aimed at reducing diabetes distress in adolescents with Type 1 Diabetes Mellitus. The intervention will be delivered by trained behavioral health providers in real-world settings, comparing in-person and telehealth approaches. A total of 360 teens will be enrolled and randomized to receive either the STePS intervention or an educational control group across six diverse study sites in the country.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the emotional well-being and diabetes management of teenagers with Type 1 Diabetes.
How similar studies have gone: Previous studies have shown promising results for similar interventions aimed at reducing diabetes distress in adolescents, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Eligibility criteria includes: * T1D diagnosis for at least 1-year, * using daily basal/bolus insulin, * fluent in English, * able to provide caregiver consent and teen assent to participate * able to access telehealth via a digital device. We will focus recruitment on participants from populations under-represented in diabetes research (e.g., racial and ethnic minorities, families of low SES, using public aid, or living in rural communities). Exclusion Criteria: To increase generalizability into typical clinical practice, exclusion criteria are minimal and include: * cognitive or developmental disorders, * participants cannot be a ward of the state.
Where it's running
-
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Jill Weissberg-Benchell, Ph.D. — Ann & Robert H Lurie Children's Hospital of Chicago
- Study coordinator: Jill Weissberg-Benchell Professor, Ph.D.
- Email: jwbenchell@luriechildrens.org
- Phone: 312-227-3419
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system
This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.
-
New gene therapies VV-14299 and VV-14300 for adults with Type 1 Diabetes failing automated insulin delivery
This study tests VV-14299 and VV-14300, or VV-14300 alone, in adults with long-standing Type 1 Diabetes whose blood sugar remains poorly controlled despite using an automated insulin delivery system.
-
Oral verapamil in newly diagnosed children and teens with type 1 diabetes
This study tests whether taking verapamil by mouth can help preserve pancreatic beta cells and reduce insulin needs in kids and teens with recently diagnosed type 1 diabetes.
-
Preventing device-related skin rashes in kids with type 1 diabetes using hydrocolloid vs silicone patches
This study tests whether silicone-based or hydrocolloid patches help prevent recurring skin irritation from insulin pumps or CGMs in children and teens with type 1 diabetes.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.